Independence Products Limited

Graphite invested in Independence Products Limited (“IPL"), a supplier of prescribed infection prevention products to chronic care patients.

IPL is a distributor of a focused range of infection prevention products, primarily to patients with renal conditions, for use outside the hospital setting. IPL’s products are protected by patents and listed on the NHS Drug Tariff, which allows for them to be offered on prescription. IPL holds a Dispensing Appliance Contractor (‘DAC’) Licence which allows it to receive those prescriptions and distribute its products directly to patients, to interact with them and control the customer relationship. IPL distributes products from its warehouse in Nottingham, with the majority of orders on repeat prescription.

At acquisition, IPL focused on patients with kidney conditions, with this population particularly susceptible to water-borne infections. IPL’s target population is growing steadily and the company is driving further penetration though awareness and education campaigns for patients and prescribing practitioners, supported by clinical evidence. As sufferers of a chronic condition, patients have a repeat need for IPL’s products.

Graphite has established a strong leadership team, with key hires made shortly post investment to drive platform development. We are investing in systems and technology to unify information provision and drive patient service, and are scaling marketing and commercial activities to drive further penetration across the renal market and parallel patient populations. We will continue to diversify IPL’s product range to access other hospital units through both NPD and M&A, with the business’ first acquisition, PML, providing strong NPD capabilities.